Cargando…

Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial

BACKGROUND: In a simulation based on a pharmacokinetic model we demonstrated that increasing the erythropoiesis stimulating agents (ESAs) half-life or shortening their administration interval decreases hemoglobin variability. The benefit of reducing the administration interval was however lessened b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Forni, Valentina, Bianchi, Giorgia, Ogna, Adam, Salvadé, Igor, Vuistiner, Philippe, Burnier, Michel, Gabutti, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3733800/ https://www.ncbi.nlm.nih.gov/pubmed/23870287 http://dx.doi.org/10.1186/1471-2369-14-157

Ejemplares similares

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
por: Arrieta, Javier, et al.
Publicado: (2014)

Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations
por: Carrera, Fernando, et al.
Publicado: (2009)

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
por: Akizawa, Tadao, et al.
Publicado: (2020)

Extended dosing of darbepoetin alfa in peritoneal dialysis patients
por: Feriani, Mariano, et al.
Publicado: (2011)

Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study
por: Canaud, Bernard, et al.
Publicado: (2008)

Haemodynamic consequences of changing potassium concentrations in haemodialysis fluids
por: Gabutti, Luca, et al.
Publicado: (2011)

New anthropometry-based age- and sex-specific reference values for urinary 24-hour creatinine excretion based on the adult Swiss population
por: Forni Ogna, Valentina, et al.
Publicado: (2015)

Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia
por: Wauters, Isabelle, et al.
Publicado: (2006)

Acute onset anterior uveitis after darbepoetin alfa infusion
por: Li, Jonathan, et al.
Publicado: (2015)

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe
por: Deger, Melike, et al.
Publicado: (2012)

Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
por: Choi, Peter, et al.
Publicado: (2013)

The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients
por: AlKharboush, Hanan, et al.
Publicado: (2020)

A prospective observational study comparing a non-operator dependent automatic PWV analyser to pulse pressure, in assessing arterial stiffness in hemodialysis
por: Salvadé, Igor, et al.
Publicado: (2015)

A pharmacist‐managed dosing algorithm for darbepoetin alfa and iron sucrose in hemodialysis patients: A randomized, controlled trial
por: van den Oever, Francisca Johanna, et al.
Publicado: (2020)

Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy‐induced anemia
por: Boccia, Ralph V., et al.
Publicado: (2016)

Determination of reference ranges for immature platelet and reticulocyte fractions and reticulocyte hemoglobin equivalent
por: Morkis, Iuri Vicente Camargo, et al.
Publicado: (2016)

Iron status and erythropoiesis response to darbepoetin alfa in dogs with chronic kidney disease
por: BHAMARASUTA, Chayanont, et al.
Publicado: (2021)

Reticulocyte hemoglobin equivalent to detect thalassemia and thalassemic hemoglobin variants
por: Sudmann, Å A, et al.
Publicado: (2012)

Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study
por: Schaefer, Franz, et al.
Publicado: (2015)

Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents
por: Lee, Sung-Eun, et al.
Publicado: (2018)

Comparison of the Pharmacokinetic–Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers
por: Kim, Seokuee, et al.
Publicado: (2018)

Acquired Pure Red Cell Aplasia Following Recombinant Erythropoietin (Darbepoetin-alfa) Therapy
por: Padhi, Somanath, et al.
Publicado: (2020)

Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study
por: Nangaku, Masaomi, et al.
Publicado: (2021)

Hypoxia-inducible factor prolyl hydroxylase domain inhibitor may maintain hemoglobin synthesis at lower serum ferritin and transferrin saturation levels than darbepoetin alfa
por: Ogawa, Chie, et al.
Publicado: (2021)

Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial
por: Maruyama, Shoichi, et al.
Publicado: (2023)

Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients
por: Barbieri, Carlo, et al.
Publicado: (2016)

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
por: Glaspy, J A, et al.
Publicado: (2002)

Darbepoetin Versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
por: Ots, Pilar Ma Samper, et al.
Publicado: (2008)

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)
por: McMurray, John J.V., et al.
Publicado: (2013)

Prevalence and Diagnostic Approach to Sleep Apnea in Hemodialysis Patients: A Population Study
por: Forni Ogna, Valentina, et al.
Publicado: (2015)

Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study
por: Donck, Jan, et al.
Publicado: (2014)

Clinical Benefits of an Adherence Monitoring Program in the Management of Secondary Hyperparathyroidism with Cinacalcet: Results of a Prospective Randomized Controlled Study
por: Forni Ogna, Valentina, et al.
Publicado: (2013)

Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open‐label, parallel‐group, noninferiority phase III trial
por: Liu, Bicheng, et al.
Publicado: (2022)

C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis
por: Bastos, Kleyton, et al.
Publicado: (2012)

Reticulocyte counts and their relation to hemoglobin levels in trauma patients
por: Otterman, M, et al.
Publicado: (2008)

Persona di cera/
por: Tynianov, IU. N. 1894-1943 (IUrii Nikolaevich)

Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open‐label, parallel‐group, non‐inferiority Phase III trail
por: Chen, Nan, et al.
Publicado: (2022)

JR‐131, a Biosimilar of Darbepoetin Alfa, for the Treatment of Hemodialysis Patients With Renal Anemia: A Randomized, Double‐Blinded, Parallel‐Group Phase 3 Study
por: Nishi, Shinichi, et al.
Publicado: (2019)

Long‐Term Safety and Efficacy of JR‐131, a Biosimilar of Darbepoetin Alfa, in Japanese Patients With Renal Anemia Undergoing Hemodialysis: Phase 3 Prospective Study
por: Nishi, Shinichi, et al.
Publicado: (2019)

Darbepoetin alfa is more potent in vivo and can be administered less frequently than rHuEPO
por: Egrie, J, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_mcud32gaoi3q319m0v4ansce49